Congruence Therapeutics Announces Close of Series A Extension, Bringing Total Round to Over US$65 Million

Congruence Therapeutics, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital's Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.

NewsGuest UserMarch 16, 2023BIOOQuébecCongruence Therpeutics Inc., biotechnology, drug discovery